Delivery Order SPE2DB25D9348-SPE2DB25FNMQC
Award Date
1/10/25
Potential Completion Date
2/3/25
Potential Value
$82K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $82,041.50 contract is for the delivery of 4,567,268,549 units of the oncology medication Keytruda (100 mg/4 ml vial) with a performance period ending on March 4, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $82,041.50, is for the delivery of 4,567,006,955 units of Keytruda 100 mg/4 ml vial, a medication used in cancer treatment. The contract has an ultimate completion date of February 7, 2025. This delivery order contract is part of a larger Indefinite Delivery Contract (IDC) valued at...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at $82,041.50 and covers the delivery of Keytruda 100 mg/4 ml vials to support the medical supply needs of military healthcare facilities. The contract is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a larger single-award Indefinite Delivery Contract...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 4,563,469,465 units of the pharmaceutical product KEYTRUDA 100 MG/4 ML VIAL 4ML. The contract has a completion date of February 12, 2024 and a potential value of $80,218.40. This delivery order is part of a larger indefinite delivery contract held by DMS Pharmaceutical Group with DLA to provide various pharmaceutical and medical supplies...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide 4,564,751,606 units of Keytruda 100 mg/4 mL vial. The firm-fixed-price contract, valued at $80,218.40, runs through June 14, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued at up to $499,999,999, which was awarded by the DLA to fulfill the recurring...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $77,505.20 contract is for the delivery of 4,560,628,829 units of the oncology drug Keytruda (100 mg/4 ml vial) with a completion date of May 8, 2023. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $49,137.36 contract is for the provision of KEYTRUDA 100MG/4ML 1S, a specialized pharmaceutical product. The contract is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at up to $112,399.98 and has an ultimate completion date of July 23, 2024. It is for the delivery of Keytruda 100 mg/4 ml vials. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025....
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $40,142.85 firm fixed-price contract is for the supply of Keytruda 100 mg/4 ml vial. The contract has an ultimate completion date of July 3, 2024. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which allows the agency to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $77,505.20 contract is for the delivery of 4,560,538,361 units of Keytruda 100 mg/4 ml vial (4 ml) to support the recurring medical supply needs of military healthcare facilities. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the...